Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;94(10):4712-4718.
doi: 10.1002/jmv.27909. Epub 2022 Jun 10.

Antibody response three months after SARS-CoV-2 infection

Affiliations

Antibody response three months after SARS-CoV-2 infection

Efdal Oktay Gültekin et al. J Med Virol. 2022 Oct.

Abstract

The coronavirus disease-19 (COVID-19) pandemic became the greatest public health challenge globally. In our study, it was aimed to determine the antibody levels in the third month after the COVID-19 infection and the symptoms that continued until the third month from the onset of the infection. One hundred people who applied to Tarsus State Hospital with the suspicion of COVID-19 and were positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by real-time reverse transcriptase-polymerase chain reaction were included. We collected serum samples from individuals, who were 3 months postinfection, and tested them in anti-SARS-CoV-2 Quanti-Vac ELISA IgG kit coated with recombinant S1 antigen for testing SARS-CoV-2 antibodies. Antibody levels were found to be higher in those aged ≥55 years, nonsmokers, those with comorbidities, and those who were hospitalized. The four most common symptoms that individuals initially encounter; are weakness, muscle and joint pain, loss of taste and smell, and cough. In 3 months after COVID-19 infection, the most common four symptoms are; muscle and joint pain, insomnia, fatigue, and other problems were determined. In conclusion; more research is needed to determine threshold levels of serum antibodies that could prevent reinfection of SARS-CoV-2.

Keywords: SARS coronavirus; immune responses; immunoglobulin; infection; virus classification.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ozgur D, Tutuncu E. COVID‐19 enfeksiyonu geçiren ve geçirmeyen sağlık çalışanlarında iki doz inaktive SARS‐CoV‐2 aşısı sonrası antikor yanıtı: prospektif gözlemsel Calışma. Mikrobiyol Bul. 2022;56(1):36‐48. 10.5578/mb.20229904 - DOI - PubMed
    1. ZHAO J, Yuan Q, Wang H, et al. Antibody responses to SARS‐CoV‐2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2027‐2034. - PMC - PubMed
    1. Yao L, Wang GL, Shen Y, et al. Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection. J Infect Dis. 2021;224.4:586‐594. - PMC - PubMed
    1. Kumar N, Hameed SK, Babu GR, et al. Descriptive epidemiology of SARS‐CoV‐2 infection in Karnataka state, South India: transmission dynamics of symptomatic vs. asymptomatic infections. EClinicalMedicine. 32, 2021:100717. - PMC - PubMed
    1. Huang C, Huang L, Wang Y, et al. 6‐Month consequences of COVID‐19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220‐232. - PMC - PubMed

Publication types